From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: Diagnosis and management

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 10-16

  Lemoine, Maud ^a,b   Serfaty, Lawrence ^a,b   Capeau, Jacqueline ^a,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL TENON   (France)

Author keywords

Fibrosis; HIV; HIV HCV coinfection; NAFLD; NASH

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALCOHOL; ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; DIDANOSINE; GLITAZONE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INSULIN SENSITIZING AGENT; LIVER PROTECTIVE AGENT; METFORMIN; PIOGLITAZONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ALCOHOL CONSUMPTION; BLOOD CHEMISTRY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC LIVER DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; ELASTOGRAPHY; EPIDEMIOLOGICAL DATA; FATTY LIVER; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MAGNETIC RESONANCE ELASTOGRAPHY; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

FATTY LIVER; HEPATITIS; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; RISK FACTORS;

EID: 84055192760     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ef599     Document Type: Review

References (51)

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The 'Mortalité 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
3. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124-131.
5. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/ NASH based on the EASL 2009 special conference. J Hepatol 2010; 53:372-384.
6. Mathurin P, Gonzalez F, Kerdraon O, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006; 130:1617-1624.
7. Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34:428-434.
8. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genet 2008; 40:1461-1465.
9. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250-257.
10. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50:464-473.
11. Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol 2008; 20:1194-1204.
12. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59:969-974.
13. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-873.
14. Mohammed SS, Aghdassi E, Salit IE, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45:432-438.
15. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006; 20:387-395.
16. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-442.
17. Loulergue P, Callard P, Bonnard P, Pialoux G. Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45:365.
18. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 11-16.
19. Blackard JT, Welge JA, Taylor LE, et al. HIV mono-infection is associated with FIB-4 - a noninvasive index of liver fibrosis - in women. Clin Infect Dis 2011; 52:674-680.
20. Mendeni M, Foca E, Gotti D, et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis 2011; 52:1164-1173.
21. DallaPiazza M, Amorosa VK, Localio R, et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10:116.
22. Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PloS One 2010; 5:e10106.
23. Jiang W, Ledermann MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
24. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-1155.
25. Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Molec Med 2010; 16:218-229.
26. Crum-Cianflone N, Krause D, Wessman D, et al. Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons. HIV Med 2011; 12:463-471.
27. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
28. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906.
29. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48:792-798.
30. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using noninvasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Therapeut 2007; 25:207-218.
31. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50:1072-1078.
32. Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in nonalcoholic fatty liver disease. Liver Int 2009; 29:1431-1438.
33. Chen J, Talwalkar JA, Yin M, et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259:749-756.
34. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51:454-462.
35. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010; 59:1279-1287.
36. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026-1032.
37. Castera L, Loko MA, Le Bail B, et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Therapeut 2007; 26 (11-12):1489-1498.
38. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a metaanalysis of the risk factors. Hepatology 2010; 52:71-78.
39. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20:525-531.
40. Rodriguez-Torres M, Govindarajan S, Sola R, et al. Hepatic steatosis in HIV/ HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48:756-764.
41. Loko MA, Bani-Sadr F, Winnock M, et al. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepatitis 2011; 18:e307-e314.
42. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51:121-129.
43. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J Hepatol 2008; 48:993-999.
44. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52:79-104.
45. Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96:2601-2608.
46. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135:100-110.
47. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51:445-453.
48. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-1685.
49. Ratziu V. Multicentric, double-blind, randomised-controlled trial (RCT) of high dose ursodeoxycholic acid in patients with NASH. Hepatology 2009; 50 (Suppl.1):49.
50. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537-1543.
51. Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198-1209.